Dr. Michael Mina

Truvian Health, a diagnostics company focused on transforming decentralized healthcare, has appointed Michael J. Mina, MD, PhD, as Chief Medical and Strategy Officer. 

The announcement follows the recent FDA clearance of Truvian’s TruVerus™, a multimodal blood analyzer designed to expand access to near-patient blood testing.

In his new role, Dr. Mina will lead clinical and regulatory strategy while advancing high-impact partnerships across the biomedical and technology sectors to accelerate commercialization and market adoption. His leadership will support Truvian’s efforts to modernize diagnostic delivery and decentralize traditional laboratory testing models.

Dr. Mina is widely recognized for his work at the intersection of immunology, epidemiology, diagnostics, and public health innovation. A former professor at the Harvard T.H. Chan School of Public Health and Harvard Medical School, he has significantly influenced modern understanding of how diagnostics drive disease prevention and health system resilience. During the COVID-19 pandemic, he became a leading global advocate for innovative testing strategies, advising policymakers and industry leaders worldwide.

Previously, Dr. Mina served as Associate Director of Molecular Diagnostics at Brigham and Women’s Hospital and the Broad Institute. An experienced biotech entrepreneur and lecturer at MIT Sloan, he brings deep expertise in scaling next-generation diagnostics and digital health solutions aligned with Truvian’s mission.